Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuel Grez

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Blood|May 1, 2010
Dimer-tetramer transition controls RUNX1/ETO leukemogenic activityChristian Wichmann, Yvonne Becker, Linping Chen-Wichmann, et al.
Biomaterials|August 22, 2015
TALEN-mediated functional correction of X-linked chronic granulomatous disease in patient-derived induced pluripotent stem cellsAnne-Kathrin Dreyer, Dirk Hoffmann, Nico Lachmann, et al.
The Biochemical Journal|September 30, 2015
A new level of regulation in gluconeogenesis: metabolic state modulates the intracellular localization of aldolase B and its interaction with liver fructose-1,6-bisphosphataseCristian A Droppelmann, Doris E Sáez, Joel L Asenjo, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 5, 2012
Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicingKerstin B Kaufmann, Christian Brendel, Julia D Suerth, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 16, 2012
Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicityJulia D Suerth, Tobias Maetzig, Martijn H Brugman, et al.
Oncotarget|September 24, 2015
Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in miceHelga Weber, Pamela Leal, Stefan Stein, et al.
Human Gene Therapy Methods|March 16, 2013
Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapyChristian Brendel, Walther Hänseler, Vital Wohlgensinger, et al.
Oncogene|August 11, 2018
Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansionLinping Chen-Wichmann, Marina Shvartsman, Caro Preiss, et al.
Journal of Virology|June 15, 2012
Safer, silencing-resistant lentiviral vectors: optimization of the ubiquitous chromatin-opening element through elimination of aberrant splicingSean Knight, Fang Zhang, Uta Mueller-Kuller, et al.
Human Gene Therapy. Clinical Development|April 18, 2018
Non-Clinical Efficacy and Safety Studies on G1XCGD, a Lentiviral Vector for Ex Vivo Gene Therapy of X-Linked Chronic Granulomatous DiseaseChristian Brendel, Michael Rothe, Giorgia Santilli, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Blood|May 1, 2010
Dimer-tetramer transition controls RUNX1/ETO leukemogenic activityChristian Wichmann, Yvonne Becker, Linping Chen-Wichmann, et al.
Biomaterials|August 22, 2015
TALEN-mediated functional correction of X-linked chronic granulomatous disease in patient-derived induced pluripotent stem cellsAnne-Kathrin Dreyer, Dirk Hoffmann, Nico Lachmann, et al.
The Biochemical Journal|September 30, 2015
A new level of regulation in gluconeogenesis: metabolic state modulates the intracellular localization of aldolase B and its interaction with liver fructose-1,6-bisphosphataseCristian A Droppelmann, Doris E Sáez, Joel L Asenjo, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 5, 2012
Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicingKerstin B Kaufmann, Christian Brendel, Julia D Suerth, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 16, 2012
Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicityJulia D Suerth, Tobias Maetzig, Martijn H Brugman, et al.
Oncotarget|September 24, 2015
Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in miceHelga Weber, Pamela Leal, Stefan Stein, et al.
Human Gene Therapy Methods|March 16, 2013
Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapyChristian Brendel, Walther Hänseler, Vital Wohlgensinger, et al.
Oncogene|August 11, 2018
Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansionLinping Chen-Wichmann, Marina Shvartsman, Caro Preiss, et al.
Journal of Virology|June 15, 2012
Safer, silencing-resistant lentiviral vectors: optimization of the ubiquitous chromatin-opening element through elimination of aberrant splicingSean Knight, Fang Zhang, Uta Mueller-Kuller, et al.
Human Gene Therapy. Clinical Development|April 18, 2018
Non-Clinical Efficacy and Safety Studies on G1XCGD, a Lentiviral Vector for Ex Vivo Gene Therapy of X-Linked Chronic Granulomatous DiseaseChristian Brendel, Michael Rothe, Giorgia Santilli, et al.
Pageof 8